Immunotherapy with Antiangiogenics in NSCLC – OncLive
OncLive |
Immunotherapy with Antiangiogenics in NSCLC
OncLive Marina Chiara Garassino, MD: The IMpower results are really important because they suggested that the combination of chemotherapy/angiogenics/immunotherapy is important. And we have the results only on the progression-free survival, so this is an … |
